Stengone Carmine N.insider trades
In SEC Form 4 filings, Stengone Carmine N. is listed as CEO and President of Contineum Therapeutics, Inc. (CTNM). In the last 90 days, Stengone Carmine N. sold $41.1K of Contineum Therapeutics, Inc. (CTNM) on the open market and bought none. The sale was reported under a 10b5-1 trading plan.
Companies and roles
| Company | Role | Transactions | Last filed |
|---|---|---|---|
| CTNMContineum Therapeutics, Inc. | CEO and President | 3 | Sep 8 |
Cluster buys
No cluster buy in the last 90 days included a purchase by this insider (two or more insiders buying within 14 days).
Form 4 historysince 2026-09-08
| Company | Traded | Filed | Type | Shares | Price | Value | Owned after | 10b5-1 plan | Filing |
|---|---|---|---|---|---|---|---|---|---|
| CTNMContineum Therapeutics, Inc. | Sep 8 | Sep 8 | M | 2,500 | $1.01 | $2,525 | 19,717 | Yes | Form 4 |
| CTNMContineum Therapeutics, Inc. | Sep 8 | Sep 8 | S | 2,500 | $16.46 | Sale −$41,142 | 17,217 | Yes | Form 4 |
| CTNMContineum Therapeutics, Inc. | Sep 8 | Sep 8 | M · derivative | 2,500 | $1.01 | $2,525 | 274,430 | Yes | Form 4 |
Published from this insider's public Form 4 filings on SEC EDGAR; the name is shown as filed. Named in a filing and want this page removed? See the privacy policy.